Traductor

29 September 2010

NICE draft guidance recommends use of Roche's Herceptin in certain patients with gastric cancer

In draft guidance published Wednesday, the National Institute for Health and Clinical Excellence recommended use of Roche's Herceptin (trastuzumab) for certain patients with metastatic gastric cancer who have high levels of HER2. The guidance recommends the drug in combination with cisplatin and Xeloda (capecitabine) or 5-fluorouracil, for people who have not received prior treatment for their metastatic disease and whose tumours express high levels of HER2. Andrew Dillon, chief executive of NICE said that the committee "concluded that trastuzumab was cost-effective in this patient group," adding that the drug in "this group of patients fitted the criteria for consideration for appraising a life-extending, end-of-life treatment."

Reference Articles
UK NICE backs some Herceptin use in gastric cancer - (Forexyard)
UK's NICE backs Roche's Herceptin in metastatic stomach cancer - (Morningstar)
Draft NICE guidance recommends a new treatment for certain patients with metastatic gastric cancer - (NICE)

**Published in "First Word"

No comments:

Post a Comment

CONTACTO · Aviso Legal · Política de Privacidad · Política de Cookies

Copyright © Noticia de Salud